Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

To design rational therapies for JAK2-driven hematological malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2. In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were constitutively active, and gene expression profili...

Descripción completa

Detalles Bibliográficos
Autores principales: Waibel, Michaela, Solomon, Vanessa S., Knight, Deborah A., Ralli, Rachael A., Kim, Sang-Kyu, Banks, Kellie-Marie, Vidacs, Eva, Virely, Clemence, Sia, Keith C.S., Bracken, Lauryn S., Collins-Underwood, Racquel, Drenberg, Christina, Ramsey, Laura B., Meyer, Sara C., Takiguchi, Megumi, Dickins, Ross A., Levine, Ross, Ghysdael, Jacques, Dawson, Mark A., Lock, Richard B., Mullighan, Charles G., Johnstone, Ricky W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898474/
https://www.ncbi.nlm.nih.gov/pubmed/24268771
http://dx.doi.org/10.1016/j.celrep.2013.10.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898474/
https://www.ncbi.nlm.nih.gov/pubmed/24268771
http://dx.doi.org/10.1016/j.celrep.2013.10.038

Ejemplares similares